An overview of investigational toxin-directed therapies for the adjunctive management of Bacillus anthracis infection and sepsis

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Expert Opinion on Investigational Drugs

• Publication date

  2015-06-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/13543784.2015.1041587PMID 25920540PMCID PMC5579489
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy of ETI-204 Monoclonal Antibody as an Adjunct Therapy in a New Zealand White Rabbit Partial Survival Model for Inhalational Anthrax

  2015cited by this paper
• Centers for Disease Control and Prevention Expert Panel Meetings on Prevention and Treatment of Anthrax in Adults

  2014influential reference
• Combination Therapy with Antibiotics and Anthrax Immune Globulin Intravenous (AIGIV) Is Potentially More Effective than Antibiotics Alone in Rabbit Model of Inhalational Anthrax

  2014cited by this paper
• Targeted Silencing of Anthrax Toxin Receptors Protects against Anthrax Toxins*

  2014cited by this paper
• Two Decades of Mortality Trends Among Patients With Severe Sepsis: A Comparative Meta-Analysis*

  2014cited by this paper
• Designing inhibitors of anthrax toxin

  2014cited by this paper
• Anthrax lethal and edema toxins in anthrax pathogenesis.

  2014cited by this paper
• Preparation and Evaluation of Human-Murine Chimeric Antibody against Protective Antigen of Bacillus anthracis

  2014cited by this paper
• Remote monitoring of the progression of primary pneumonic plague in Brown Norway rats in high-capacity, high-containment housing.

  2014cited by this paper
• Anthrax lethal factor inhibitors as potential countermeasure of the infection.

  2014cited by this paper
• Confirmed Bacillus anthracis Infection among Persons Who Inject Drugs, Scotland, 2009–2010

  2014cited by this paper
• Added Benefit of Raxibacumab to Antibiotic Treatment of Inhalational Anthrax

  2014cited by this paper
• Injectional anthrax - new presentation of an old disease.

  2014cited by this paper
• Lethal Factor and Anti-Protective Antigen IgG Levels Associated with Inhalation Anthrax, Minnesota, USA

  2014cited by this paper
• A Human/Murine Chimeric Fab Antibody Neutralizes Anthrax Lethal Toxin In Vitro

  2013cited by this paper
• Designed Azolopyridinium Salts Block Protective Antigen Pores In Vitro and Protect Cells from Anthrax Toxin

  2013cited by this paper
• Evaluation of Intravenous Anthrax Immune Globulin for Treatment of Inhalation Anthrax

  2013influential reference
• Identification of Small Molecules That Inhibit the Interaction of TEM8 with Anthrax Protective Antigen Using a FRET Assay

  2013cited by this paper
• Effect of Anthrax Immune Globulin on Response to BioThrax (Anthrax Vaccine Adsorbed) in New Zealand White Rabbits

  2013cited by this paper
• Bacillus anthracis Protective Antigen Kinetics in Inhalation Spore-Challenged Untreated or Levofloxacin/Raxibacumab-Treated New Zealand White Rabbits

  2013cited by this paper
• Cyclodextrin derivatives as anti-infectives.

  2013cited by this paper
• Small-Molecule Inhibitors of Lethal Factor Protease Activity Protect against Anthrax Infection

  2013cited by this paper
• Severe sepsis and septic shock.

  2013cited by this paper
• Inhibitors of Bacillus anthracis edema factor.

  2013cited by this paper
• B. anthracis associated cardiovascular dysfunction and shock: the potential contribution of both non-toxin and toxin components

  2013cited by this paper
• B. anthracis edema toxin increases cAMP levels and inhibits phenylephrine-stimulated contraction in a rat aortic ring model.

  2013cited by this paper
• Anthrax and the inflammasome.

  2012cited by this paper
• Small molecule inhibitors of Bacillus anthracis protective antigen proteolytic activation and oligomerization.

  2012influential reference
• Delayed Toxicity Associated with Soluble Anthrax Toxin Receptor Decoy-Ig Fusion Protein Treatment

  2012cited by this paper
• Protective antigen antibody augments hemodynamic support in anthrax lethal toxin shock in canines.

  2012cited by this paper
• A FRET-Based High Throughput Screening Assay to Identify Inhibitors of Anthrax Protective Antigen Binding to Capillary Morphogenesis Gene 2 Protein

  2012cited by this paper
• A Novel Mechanism for Antibody-based Anthrax Toxin Neutralization

  2012cited by this paper
• Pharmacophore Selection and Redesign of Non-nucleotide Inhibitors of Anthrax Edema Factor

  2012cited by this paper
• New insights into the biological effects of anthrax toxins: linking cellular to organismal responses.

  2012cited by this paper
• Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain.

  2012cited by this paper
• Anthrax toxin protective antigen—Insights into molecular switching from prepore to pore

  2012cited by this paper
• Small Molecule Inhibitors of Anthrax Toxin–induced Cytotoxicity Targeted Against Protective Antigen

  2012cited by this paper
• Human monoclonal antibodies generated following vaccination with AVA provide neutralization by blocking furin cleavage but not by preventing oligomerization.

  2012cited by this paper
• Identification of New Dominant-Negative Mutants of Anthrax Protective Antigen Using Directed Evolution

  2012cited by this paper
• Novel approaches to the treatment of systemic anthrax.

  2012cited by this paper
• An overview of anthrax infection including the recently identified form of disease in injection drug users

  2012cited by this paper
• Inter-&agr; Inhibitor Proteins: A Novel Therapeutic Strategy for Experimental Anthrax Infection

  2011cited by this paper
• Phase I Study Evaluating the Safety and Pharmacokinetics of MDX-1303, a Fully Human Monoclonal Antibody against Bacillus anthracis Protective Antigen, in Healthy Volunteers

  2011cited by this paper
• Mouse Monoclonal Antibodies to Anthrax Edema Factor Protect against Infection

  2011cited by this paper
• Anthrax edema toxin has cAMP-mediated stimulatory effects and high-dose lethal toxin has depressant effects in an isolated perfused rat heart model.

  2011cited by this paper
• Delayed treatment with W1-mAb, a chimpanzee-derived monoclonal antibody against protective antigen, reduces mortality from challenges with anthrax edema or lethal toxin in rats and with anthrax spores in mice

  2011cited by this paper
• Bis-Halogen-Anthraniloyl-Substituted Nucleoside 5′-Triphosphates as Potent and Selective Inhibitors of Bordetella pertussis Adenylyl Cyclase Toxin

  2011cited by this paper
• The Potential Contributions of Lethal and Edema Toxins to the Pathogenesis of Anthrax Associated Shock

  2011cited by this paper
• Tumor Endothelium Marker-8 Based Decoys Exhibit Superiority over Capillary Morphogenesis Protein-2 Based Decoys as Anthrax Toxin Inhibitors

  2011cited by this paper
• Emerging themes of cAMP regulation of the pulmonary endothelial barrier.

  2011cited by this paper
• Inhibition of the adenylyl cyclase toxin, edema factor, from Bacillus anthracis by a series of 18 mono- and bis-(M)ANT-substituted nucleoside 5′-triphosphates

  2011cited by this paper
• New Insights into the Biological Effects of Anthrax Toxins: Linking Cellular to Organismal Responses

  2011cited by this paper
• Antidotes to anthrax lethal factor intoxication. Part 2: structural modifications leading to improved in vivo efficacy.

  2011cited by this paper
• Inhibition of anthrax toxins with a bispecific monoclonal antibody that cross reacts with edema factor as well as lethal factor of Bacillus anthracis.

  2011cited by this paper
• Anthrax infection.

  2011cited by this paper
• The unfolding story of anthrax toxin translocation

  2011cited by this paper
• Antibodies Against Anthrax: Mechanisms of Action and Clinical Applications

  2011cited by this paper
• Structure-based design of a heptavalent anthrax toxin inhibitor.

  2011cited by this paper
• Structure-activity relationships for the interactions of 2'- and 3'-(O)-(N-methyl)anthraniloyl-substituted purine and pyrimidine nucleotides with mammalian adenylyl cyclases.

  2011cited by this paper
• Passive vaccination with a human monoclonal antibody: generation of antibodies and studies for efficacy in Bacillus anthracis infections.

  2011cited by this paper
• Antidotes to anthrax lethal factor intoxication. Part 1: Discovery of potent lethal factor inhibitors with in vivo efficacy.

  2010cited by this paper
• The Use of Anthrax and Orthopox Therapeutic Antibodies from Human Origin in Biodefense

  2010cited by this paper
• Neutralizing Monoclonal Antibody to Edema Toxin and Its Effect on Murine Anthrax

  2010cited by this paper
• Heterodimeric integrin complexes containing β1-integrin promote internalization and lethality of anthrax toxin

  2010cited by this paper
• Recombinant Anthrax Toxin Receptor-Fc Fusion Proteins Produced in Plants Protect Rabbits against Inhalational Anthrax

  2010cited by this paper
• Use of allostery to identify inhibitors of calmodulin-induced activation of Bacillus anthracis edema factor

  2010cited by this paper
• Consequences and Utility of the Zinc-Dependent Metalloprotease Activity of Anthrax Lethal Toxin

  2010cited by this paper
• Case records of the Massachusetts General Hospital. Case 25-2010. A 24-year-old woman with abdominal pain and shock.

  2010cited by this paper
• Selective and potent furin inhibitors protect cells from anthrax without significant toxicity.

  2010cited by this paper
• Current and future medical approaches to combat the anthrax threat.

  2010cited by this paper
• Select human anthrax protective antigen epitope-specific antibodies provide protection from lethal toxin challenge.

  2010cited by this paper
• Fusion protein of Δ27LFn and EFn has the potential as a novel anthrax toxin inhibitor

  2009cited by this paper
• Potent neutralization of anthrax edema toxin by a humanized monoclonal antibody that competes with calmodulin for edema factor binding

  2009cited by this paper
• Raxibacumab for the treatment of inhalational anthrax.

  2009influential reference
• Receptors of anthrax toxin and cell entry.

  2009cited by this paper
• Distinct interactions of 2'- and 3'-O-(N-methyl)anthraniloyl-isomers of ATP and GTP with the adenylyl cyclase toxin of Bacillus anthracis, edema factor.

  2009cited by this paper
• Investigation of New Dominant-Negative Inhibitors of Anthrax Protective Antigen Mutants for Use in Therapy and Vaccination

  2009cited by this paper
• The anthrax lethal factor and its MAPK kinase-specific metalloprotease activity.

  2009cited by this paper
• Membrane translocation by anthrax toxin.

  2009cited by this paper
• The Major Neutralizing Antibody Responses to Recombinant Anthrax Lethal and Edema Factors Are Directed to Non-Cross-Reactive Epitopes

  2009cited by this paper
• The adenylyl cyclase activity of anthrax edema factor.

  2009cited by this paper
• Molecular Analysis of the Interaction of Anthrax Adenylyl Cyclase Toxin, Edema Factor, with 2′(3′)-O-(N-(methyl)anthraniloyl)-Substituted Purine and Pyrimidine Nucleotides

  2009cited by this paper
• Isolation and Chimerization of a Highly Neutralizing Antibody Conferring Passive Protection against Lethal Bacillus anthracis Infection

  2009cited by this paper
• Anthrax toxin: pathologic effects on the cardiovascular system.

  2009cited by this paper
• Quantitative high-throughput screening identifies inhibitors of anthrax-induced cell death

  2009cited by this paper
• In Vivo Efficacy of β-Cyclodextrin Derivatives against Anthrax Lethal Toxin

  2008cited by this paper
• Anthrax-associated shock.

  2008cited by this paper
• Low molecular weight inhibitors of the protease anthrax lethal factor.

  2008cited by this paper
• Efficient Neutralization of Antibody-Resistant Forms of Anthrax Toxin by a Soluble Receptor Decoy Inhibitor

  2008cited by this paper
• Synthesis of Homopolymers and Copolymers Containing an Active Ester of Acrylic Acid by RAFT: Scaffolds for Controlling Polyvalent Ligand Display.

  2008cited by this paper
• Investigations and control measures following a case of inhalation anthrax in East London in a drum maker and drummer, October 2008.

  2008cited by this paper
• A Dual-Purpose Protein Ligand for Effective Therapy and Sensitive Diagnosis of Anthrax

  2008cited by this paper
• Discovery and development of anthrax lethal factor metalloproteinase inhibitors.

  2008cited by this paper
• Selection and characterization of human antibodies neutralizing Bacillus anthracis toxin.

  2008cited by this paper
• Novel inhibitors of anthrax edema factor.

  2008cited by this paper
• Targeting Host Cell Furin Proprotein Convertases as a Therapeutic Strategy against Bacterial Toxins and Viral Pathogens*

  2007cited by this paper
• High-Affinity, Human Antibody-Like Antibody Fragment (Single-Chain Variable Fragment) Neutralizing the Lethal Factor (LF) of Bacillus anthracis by Inhibiting Protective Antigen-LF Complex Formation

  2007cited by this paper
• A case of naturally acquired inhalation anthrax: clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factor.

  2007cited by this paper
• Anthrax lethal toxin‐induced inflammasome formation and caspase‐1 activation are late events dependent on ion fluxes and the proteasome

  2007cited by this paper
• Human Monoclonal Antibodies against Anthrax Lethal Factor and Protective Antigen Act Independently To Protect against Bacillus anthracis Infection and Enhance Endogenous Immunity to Anthrax

  2007cited by this paper

• A Review of the Efficacy of FDA-Approved B. anthracis Anti-Toxin Agents When Combined with Antibiotic or Hemodynamic Support in Infection- or Toxin-Challenged Preclinical Models

  2021cites this paper
• Anthrax prevention through vaccine and post-exposure therapy

  2020cites this paper
• Bacillus anthracis Edema Toxin Inhibits Hypoxic Pulmonary Vasoconstrictionvia Edema Factor and cAMP Mediated Mechanisms in Isolated Perfused Rat Lungs.

  2020cites this paper
• A systematic review and meta-analysis of preclinical trials testing anti-toxin therapies for B. anthracis infection: A need for more robust study designs and results

  2017cites this paper
• Obiltoxaximab Prevents Disseminated Bacillus anthracis Infection and Improves Survival during Pre- and Postexposure Prophylaxis in Animal Models of Inhalational Anthrax

  2016cites this paper
• Remote monitoring of the progression of primary pneumonic plague in Brown Norway rats in high-capacity, high-containment housing.

  2014cites this paper